Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

CORRECTED-Sanofi drug Dupixent wins U.S. FDA approval to treat asthma [Reuters]

Sanofi - American Depositary Shares (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
Company Research Source: Reuters
Sanofi drug Dupixent wins FDA approval to treat asthma | Reuters 1 Min Read (Reuters) - France’s Sanofi SA said on Friday eczema drug Dupixent was approved by the U.S. Food and Drug Administration as an additional maintenance therapy in patients with two types of asthma. Dupixent, co-developed with U.S.-based Regeneron, received approval to treat patients with eosinophilic asthma, a rare form of the disease, and those dependent on anti-inflammatory steroids. The drug acts by restraining proteins responsible for the inflammation of airways of the lungs, the root cause of asthma. Dupixent was launched in the United States in April 2017 for the treatment of moderate-to-severe eczema in adults. The drug, a key revenue driver for Sanofi, had worldwide sales of 176 million euros ($202.5 million) in the second quarter of 2018, of which 151 million euros came from the United States. The drugmaker is also co-developing Dupixent for at least seven other conditions including pediatric asthma, ch Show less Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
SNY alerts

from News Quantified
Opt-in for
SNY alerts

from News Quantified